IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2239
Positioning
Market Dominance
Manufacturing
Measuring And Control Equipment
$9.7B
Prahlad R. Singh
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = RVTY ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$RVTY REVVITY, INC. | 49 | 48 | 66 | 47 | 48.0x | 33.2x | 3.2% | 1.9% | 55.2% | 12.4% | 8.6% | 1.1% | 0.3% | 65.0x | $9.7B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
REVVITY, INC. (RVTY) receives a "Reduce" rating with a composite score of 48.6/100. It ranks #2239 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for RVTY.
View All RatingsROIC 3.0% vs WACC 7.8% (spread -4.7%)
GM 55% vs sector 44%, OM 12% vs sector 3%
Capital turnover 0.31x, R&D intensity 7.6%
Rev growth 1%, 10yr history
Interest coverage 3.1x, Net debt/EBITDA 27.9x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate REVVITY, INC. (RVTY) as a Reduce with a composite score of 48.6/100 at a current price of $97.65. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
REVVITY, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 48.6/100 places it at rank #2239 in our full universe.
Narrow
Medium
Poor
Undervalued
Gross margins of 55% signal strong pricing power.
Value factor score of 66 suggests attractive pricing.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 48.0x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
REVVITY, INC. represents a reduce based on multi-factor quantitative performance.
REVVITY, INC. receives a Reduce rating from our analysis, with a composite score of 48.6/100 and 2 out of 5 stars, ranking #2239 out of 7,333 stocks. RVTY's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 48/100, RVTY shows adequate but unremarkable business quality. The company reports a return on equity of 3.2% (sector avg: -1.9%), gross margins of 55.2% (sector avg: 44.1%), net margins of 8.6% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
RVTY's value score of 66/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 47.95x, an EV/EBITDA of 33.16x, a P/B ratio of 1.54x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
REVVITY, INC.'s investment score of 30/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 1.1% vs. a sector average of 6.7% and a return on assets of 1.9% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
RVTY is currently showing below-average momentum at 47/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 1.1% year-over-year, while a beta of 1.20 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
RVTY shows good financial stability with a score of 72/100. Key stability metrics include a beta of 1.20 and a debt-to-equity ratio of 65.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 40/100 for RVTY suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 65.00x). With a $9.7B market cap (mid-cap), REVVITY, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
RVTY offers a modest dividend yield of 0.3%. While the income contribution is relatively small, even a small dividend signals management's commitment to shareholder returns and can serve as a signal of financial discipline.
REVVITY, INC. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2239 of 7,333 overall (69th percentile). Key comparisons include ROE of 3.2% exceeding the -1.9% sector median and operating margins of 12.4% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While RVTY currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (30) would have the largest impact on the composite score.
EV/EBITDA 189% ABOVE SECTOR MEDIAN
ROE 269% BELOW SECTOR MEDIAN
Gross Margin 25% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
New York Life Investment Management LLC increased its stake in Revvity Inc. by 72.7%, acquiring an additional 11,583 shares, bringing their total ownership to 27,520 shares valued at approximately $2.41 million. This increase contributes to the 86.65% institutional ownership of the company. Recent quarterly results exceeded expectations, with an EPS of $1.70 against an estimated $1.55, and the company announced a $1 billion share buyback program and a $0.07 quarterly dividend.
U.S. stock futures declined on Tuesday ahead of December CPI data release. Major indices were trading lower with the S&P 500 down 0.12% and Nasdaq 100 down 0.19%. Key stocks in focus include Alphabet reaching $4 trillion market value, JPMorgan preparing to report Q4 earnings, Five9 expanding its Google Cloud partnership, and Revvity rising 4.92% after positive earnings guidance. Markets are pricing in a 95% likelihood of the Federal Reserve maintaining current interest rates in January.
Earlier this week, Revvity reported stronger-than-expected Q4 2025 results, with Diagnostics delivering 10% reported revenue growth and management issuing upbeat full-year 2026 guidance calling for US$2.96–US$2.99 billion in revenue and adjusted EPS of US$5.35–US$5.45. Beyond the headline beat, the combination of robust Diagnostics performance and confident 2026 outlook offers investors fresh insight into how Revvity’s higher-margin, recurring revenue mix may be developing. We’ll now explore...
Sotera Health Company (SHC) is set to report its Q4 earnings on Tuesday. The company beat revenue expectations last quarter and analysts anticipate 3.3% year-on-year revenue growth for the upcoming report. Despite a challenging environment for research tools & consumables stocks, Sotera Health has a history of exceeding Wall Street's expectations.
Danaher (DHR) is reportedly close to acquiring Masimo (MASI) for approximately $10 billion, a move that would significantly bolster Danaher's position in the medical technology sector. This acquisition, if finalized, would be Danaher's largest since its $21.4 billion purchase of Cytiva, showcasing its continued investment in biotechnology. Despite a recent decline in Masimo's stock, this deal is expected to provide Danaher with new growth opportunities given the sustained demand for medical devices.